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Abstract: Scientific and commercial interest of probiotics, prebiotics and their effect on human health
and disease has increased in the last decade. The aim of this review article is to evaluate the role
of pro- and prebiotics on the normal function of healthy skin as well as their role in the prevention
and therapy of skin disease. Lactobacilli and Bifidobacterium are the most commonly used probiotics
and thought to mediate skin inflammation, treat atopic dermatitis (AD) and prevent allergic contact
dermatitis (ACD). Probiotics are shown to decolonise skin pathogens (e.g., P. aeruginosa, S. aureus,
A. Vulgaris, etc.) while kefir is also shown to support the immunity of the skin and treat skin
pathogens through the production of antimicrobial substances and prebiotics. Finally, prebiotics
(e.g., Fructo-oligosaccharides, galacto-oligosaccharides and konjac glucomannan hydrolysates) can
contribute to the treatment of diseases including ACD, acne and photo aging primarily by enhancing
the growth of probiotics.
Keywords: probiotics; prebiotics; skin health; skin disease; dermatitis; skin infections
1. Introduction
Fermented food has been part of our diet, in addition to being used for therapeutic purposes,
as early as 7000 BC from Egyptians, Greeks and Italians [1–3]. Some of the most ancient fermented
foods used in history is wine, bread and milk products such as yoghurt. In fact, it is documented that
Georgians were using wine in their diet as early as 6000 BC, whilst fermented dairy products were
used for the treatment of diarrhea and other gastroenteric infections [4,5]. The relationship between
human health and microbiota was first mentioned in 1907, by Elie Metchnikoff, when the enhanced
longevity due to the intentionally present bacteria in yogurt was described [6]. In addition, fermented
food became famous after Werner Kollath first introduced the term “Probiotic”. The food industry has
used probiotics in their products as an aiding ingredient and/or as a preservative means since 1989 [7].
With the evolution of food processing and preservation and the consumer’s interest for a healthier
and more balanced diet, probiotics became one of the most marketable ingredients. According to the
World Health Organization (WHO), probiotics are live microorganisms that “when administered in
adequate amounts, confer a health benefit on the host” [8]. Most common species of probiotics belong
in the families of Lactobacillus, Bifidobacterium and Streptococcus [9] with the first two families being
mostly used in studies related to human health [10]. As these microorganisms are naturally found
in the gut microbiota, most studies are focused on their effects in the context of the natural function
in the gut and as preventive or therapeutic agents against disease development [11–18]. To this end,
probiotics have been used for the study and treatment of intestinal diseases such as gastroenteritis [19],
intestinal hyperpermeability [20], urinary tract infection [21], intestinal dysbiosis [22], irritable bowel
syndrome [23], Crohn’s disease [24], colon cancer [25,26], ulcerative colitis [27,28] and peptic ulcer [23].
In particular, many studies have shown their involvement in regulating signaling molecules like
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NFκB, MAPK, PPARγ, HSP, etc. by either activating or inhibiting their expression profile depending
on the microorganism studied. Such effect(s), in turn, can trigger other signaling events including
perturbations in the (i) phosphorylation content of IκBα, (ii) activation status of p38, (iii) inhibition
of nuclear binding by p65 as well as (iv) induction of PPARγ mRNA levels [29–61]. In addition,
probiotics have been extensively utilized in the context of intervention studies towards prevention
and/or treatment of a number of human diseases including those of the skin like atopic dermatitis
[AD] [62–69], allergic rhinitis [66,70,71] and wound healing [72–79] being some of the major ones
(Figure 1).
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Figure 1. The role of probiotics and prebiotics on skin health and disease including Allergic Contact
Dermatitis (ACD), Acne, Wounds, Psoriasis, Photoaging and Atopic Dermatitis (AD).
On the other hand, with the term “prebiotics” we refer to specific fermented components
that enhance changes in the composition and the activity of the gut microflora in favor to the
host [80]. Prebiotics are characterized by low dosage activity, absence of side effects and persistence
through the gut [81]. The most commonly known prebiotics are oligosaccharides (OS; e.g., glycans),
fructans ( nulin-type), sugar alcohols and complex polysaccharides (e.g., β-glucans, cellulose) [82,83].
The available literature on prebiotics and th ir effect on human health is limited, compared to the
probiotics, and it is often included in several robiotic studies. These no -digestible compounds are
known for their bifidogenic effect, which varies depending on the type of prebiotic. This is based on the
fact that long-chain OS are fermented in the entire gut whereas the short-chain ones are only processed
in the ascending colon and the caecum. Breast milk mostly consists of prebiotic OS and as being the
first food for infants; it provides the initial intestinal microbiota whose growth is supported by these
OS. Furthermore, recent studies have shown the ability of prebiotics to enhance calcium absorption
and have an effect on bone structure as well [82]. Moreover, these compounds are shown to affect
the immune system by increasing IgA, CD4+ c ll , INF-γ and IL-4 in spl en and mesenteric lymph
nodes [84–86]. Additionally, other stud es on healthy participants have shown decr ase of toxic
fermentation metabolites in the colon (e.g., [H4] tyrosine and lactose-[N]ureide) after consumption of
pro- (e.g., L. casei) and prebiotics (e.g., n9; lactulose) [87].
Finally, the skin represents the largest organ in the human body and as such, its main function
is to act as a barrier to extrinsic factors including physical, chemical and microbial threats. In this
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context, a strong symbiotic relationship between microorganisms exists that constitutes its microbiota.
This natural microflora supports the immune system in various ways including the production of
natural antimicrobial compounds (e.g., lactic acid) as well as activation of various signaling pathways
and modulation of the inflammatory response [88,89]. In this review article, we aim to focus on the
beneficial role of pro- and prebiotics on skin health as well as their therapeutic and/or preventive role
on specific skin diseases.
2. Probiotics and Prebiotics on Skin Health
There is a rather small number of studies on healthy subjects to show a beneficial effect of
probiotics on skin health (Figure 1) [18,61,90–92]. In one such study, when the L. lactis strain; H61
was supplemented on middle-aged women, daily for eight weeks, an improvement on skin elasticity
and body characteristics were observed (e.g., skin appeared more hydrated and the hair follicles had
improved) [92]. Similarly, in another such study, oral intakes of L. plantarum; HY7714 from a group
of subjects aged 41–59 years old also confirmed the effect of probiotics on increasing skin moisture,
decreasing the depth of existing wrinkles and improving the overall skin gloss and elasticity [61].
Moreover, other studies have shown that when probiotic and para-probiotic L. reuteri were administrated
orally, for 12 weeks, an increase in melanin and a decrease in Trans-Epidermal Water Loss (TEWL) were
observed [91]. Such effects are in agreement with studies utilizing other probiotics (e.g., L. rhamnosus,
B. breve Strain Yakult, L. lactis, S. thermophilus) and prebiotics (e.g., galacto-oligosaccharides; GOS)
(Figure 1) all of which have indicated (i) improved levels of skin hydration and cathepsin-L-like activity
levels (an indicator of keratinocyte differentiation and a marker of skin barrier function) as well as (ii)
reduced urine and serum phenol levels (e.g., toxic by-products formed by gut bacteria) [90,93].
3. Probiotics and Prebiotics on Skin Disease
3.1. Dermatities
3.1.1. Atopic Dermatitis
Atopic Dermatitis (AD), also known as atopic eczema, is a skin inflammatory disease that is
observed in early stages of life and is linked with allergic rhinitis, food allergies and asthma, all of
which are more prevalent in children suffering from this disease. One of the most common symptoms
of eczema, apart from itchiness, is the reduction of barrier function that leads to allergen exposure and
overall reduction of the TEWL, leading to dry skin [94]. In an AD model, allergens can penetrate the
stratum corneum, which is altered by the epidermal epithelium deformities. Moreover, symptoms
include the presence of pathogenic microorganisms, such as S. aureus, that colonize and infect the
subjects. Another significant aspect of AD is its relationship with the gut microbiota. More specifically,
the balanced microbial profile of the mucosa can promote the production of immunoglobulin A (IgA)
which supports the defensive mechanisms of the gut membrane, whilst enhancing the expression
of the Transforming Growth Factor (TGF) [95]. A relationship between the gut microflora and the
development of AD was also observed in infants at high risk for developing AD showing an increased
number of clostridia compared to control, disease free infants [96].
Specific probiotic microorganisms are shown to have a preventing role on AD and mediate the
symptoms of the disease (Figure 1). They appear to do so by influencing a number of biological
processes not only in AD but rather in a wide range of skin diseases (e.g., acne, psoriasis, photo
aging, wounds, etc.) (Table 1 and Figure 2). More specifically, in a recent study, supplementation with
L. rhamnosus in combination with L. reuteri improved the severity of eczema by 56% in children suffering
from AD [65]. Moreover, in another study, L. rhamnosus was utilized as a supplemented probiotic,
to women four weeks before delivery and six months postnatal, demonstrating to significantly reduce
the risk of children developing AD during their first seven years of age [66]. Finally, when infants
at high risk of developing AD were supplemented with a mix of probiotic microorganisms (e.g.,
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L. acidophilus, B. bifidum and B. lactis), during pregnancy and after birth, they showed a reduction of
immunoglobulin E (Ig-E) associated eczema by 40% [62].
Table 1. Probiotics and their effect on skin diseases.
Probiotics Disease Function Reference
L. rhamnosus AD 1
Improvement of severity of eczema, reduction of
risk of AD development in infants [65,66]
L. reuteri ADInfections (S. aureus)
Improvement of eczema. Blocks integrin,
Reduces cell death due to S. aureus infection [65,97]
L. delbrueckii
subspecies bulgaricus Acne Improvement of Acne symptoms (Acne Vulgaris) [98]
L. sporogenes Psoriasis Improvement of symptoms, reduction of bloodsugar levels and fever [99]
L. plantarum Photoaging
Inhibition of MMP-1, MMP-2, MMP-9 and
MMP-13 2, enhancement of procollagen
expression, inhibition of phosphorylation of Jun
N-terminal kinase, increase of
palmitoytransferase mRNA levels, decrease of
ceramide mRNA levels, reduction of wrinkles
and epidermal thickness
[100,101]
L. fermentum Infections (wounds) Production of gNO
3, increases productions of
IL-1 4 and TGF-β 5 cytokines
[102,103]
L. acidophilus
AD
ACD 6
Infections (S. aureus)
Acne
Reduction of Ig-E 7, reduction of eczema,
Increase of TGF-β, Foxp3 8, IFN-γ 9 and IL-10 10
expression, Inhibition of S. aureus infection,
reduction of acne symptoms
[62,98,104,
105]
L. casei
L. salivarius
ACD
Infections (MRSA) 11
Reduction of skin inflammation, inhibition of
IFN-γ, CD8+ T cells, increase in IL-10 production,
activation of CD4+CD25+ T cells,
inhibition of MRSA
[105–107]
B. bifidum ADAcne
Reduction of Ig-E, reduction of development of
AD in infants, reduction of Acne
Vulgaris symptoms
[62,98]
B. lactis AD Reduction of Ig-E, reduction of development ofAD in infants. [62]
B. pseudolongum ACD Reduction of allergic reaction on mice [108]
B. longum Photoaging
Prevention of TEWL 12, reduction of skin
erythema, increase of mRNA expression of CD44,
TIMP-113 and Col114.
[109]
B. breve strain Yakult Photoaging Prevention of loss of elasticity, suppression ofelastase, activation of IL-1β [38,110]
B. infantis Psoriasis Reduction of plasma TNF-α15, increase of IL-6 [111]
S. epidermidis Acne Growth inhibition of Propionibacterium acnesand Acne Vulgaris by competitive exclusion [112]
E. faecalis Acne Reduction of inflammation areas, productionof bacteriocins [113]
E. coli Nissle 1917 ACD Increase of TGF-β, Foxp3, IFN-γ andIL-10 expression [114]
Kefir grains Infections
Production of antimicrobial substances (lactic
acid, acetic acid, hydrogen peroxide,
bacteriocins), Healing of P. aeruginosa infected
wounds, Inhibition of S. aureus, S. salivarius, S.
pyogenes, P. aeruginosa, C. albicans, S. tympimurium,
L. monocytogenes and E. coli growth
[115,116]
1 Atopic Dermatitis; 2 Matrix Metalloproteinases (MMPs)-1,-2,-9,-13; 3 Nitric Oxide; 4 Interleukin 1; 5 Transforming
Growth Factor β; 6 Allergic Contact Dermatitis; 7 Immunoglobulin E; 8 Forkhead box P3; 9 Interferon gamma;
10 Interleukin 10; 11 Methicilin Resistant Staphylococcus aureus; 12 Trans Epidermal Water Loss; 13 Tissue inhibitor
of metalloproteinases 1; 14 Collagen 1; 15 Tumor Necrosis Factor.
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Figure 2. Linkage of various skin diseases with their respective mode of action through which pro-
and prebiotics exert a beneficial effect. Methicilin Resistant Staphylococcus aureus (MRSA); Trans
Epidermal Water Loss (TEWL).
3.1.2. Allergic Contact Dermatitis
Allergic contact dermatitis (ACD), also known as eczema, is caused after the skin comes in contact
with an a lergenic substance c pable of causing an allergic reaction. Symptoms vary but include skin
inflammation, itchiness, dry skin, blisters, etc. The allergic reaction is regulated by CD4+ T cells in a
manner where peptides derived from allergens activate Th2-type cytokines (produced by these CD4+
T lymphocytes) including interleukins 4, 5 and 13 [117]. Overall, pro- and prebiotics are shown to have
a preventing role on ACD and consequently mediate its symptoms (Figure 1).
L. casei is found to reduce skin inflammation either by targeting the inhibition of INF-γ (responsible
in producing CD8+ effector T cells) [106] or via mechanisms that include the involvement of regulatory
CD4+ T cells [107]. In addition, the microorganism has also been shown to increase the production
of IL-10 by promoting the activation of CD+4CD25+ Tregs thus further supporting its specific mode
of action against skin inflammation [107] (Table 1 and Figure 2). On the other hand, E. coli Nissle
1917 (EcN) is another probiotic microorganism shown to prevent ACD by means of increasing the
number of Foxp3+ cells (suppress antigen priming of lymphocytes) as well as the expression of TGF-β,
IFN- γ and IL-10 (regulatory cytokine network) thus suggesting an immunomodulatory function
against allergen-induced dermatitis [114] (Table 1 and Figure 2). Similar observations were made in
the case of the para-probiotic L. acidophilus strain L-92 which was also shown to induce the activation
of CD+4CD25+3+ Tregs and consequently suppress ACD [104] (Table 1 and Figure 2).
Finally, in another study, consumption of the prebiotic fructo-oligosaccharide resulted in
suppressed skin inflammation due to a favorable change in the population of the intestinal microbiota
by means of increasing the population of B. pseudolongum. This, in turn, has led to reduced contact
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hypersensitivity associated with proliferation of B. pseudolongum in the intestinal tract of the mice [108]
(Table 2).
Table 2. Prebiotics and their effect on skin disease.
Prebiotics Disease Function Reference
Fructo-oligosaccharides ACD Reduction of allergic reaction. [108]
Konjac glucomannan
hydrolysates (GMH) Acne
Inhibition of Acne Vulgaris and P. acnes, growth
enhancement of lactic acid bacteria. [118,119]
Galacto-oligosaccharides Photoaging
Prevention of 1 TEWL, reduction of skin
erythema, increase of mRNA expression of CD44,
2TIMP-1 and 3Col1.
[109]
Sodium Butyrate (?) Psoriasis Increases Fas, 4 TGF-β and p52 [120–123]
Oligo-saccharides Photoaging Modulation of the expression of elastase-typeproteases through elastin receptors [124,125]
1 Trans Epidermal Water Loss; 2 Tissue inhibitor of metalloproteinases 1; 3 Collagen 1; 4 Transforming Growth
Factor β.
3.2. Skin Infections
3.2.1. Wounds
Most skin infections are initiated when an opening of the skin is infected with a pathogen. Briefly,
when the cohesion of the skin is disrupted (either accidentally or as an effect of a disease) it forms
a wound which is characterized by torn skin or by a hematoma of the tissue. In the case of a torn
tissue, there are four stages descriptive of the healing process: (i) stopping the blood flow to the
damaged blood vessels (hemostasis); (ii) initiating an inflammatory response which prevents potential
pathogenic microorganisms to infect the wound and maintains the microbial balance of the skin; (iii)
stimulating production of growth factors causing (iv) proliferation of fibroblasts and production of
extracellular matrix proteins (e.g., hyaluronan and collagen) [126]. Furthermore, these stages are
characterized by the involvement of other events including generation of oxidative stress [127].
There is a great scientific interest regarding the role of skin microflora in the process of wound
healing as it has been shown that the absence of microbiota can decrease the healing time [128].
On another note, wound infections occur when exogenous bacteria become dominant over the systemic
and local factors of host resistance. Therefore, it is only when a balance is achieved between bacteria
and host that allows for the normal processes of wound healing to proceed [129]. Over the years,
scientists have turned their interest to topical application of specific probiotic microorganisms in order
to evaluate their effectiveness in preventing wound inflammation as well as improving on the speed
of the healing process itself. In one such study, when burn wounds were treated with Saccharomyces
cerevisiae an overall improvement on the healing process was observed [130]. More specifically, an
increase in the expression levels of collagen type 1 and transcription growth factor beta 1 (TGF-β1)
were observed accompanied by improved morphological and biomechanical characteristics of the
healing wounds [130].
Meticillin-resistant Staphylococcus aureus (MRSA) is one of the most widely known pathogens with
the ability to infect wounds [131]. A number of studies have shown the capacity of specific probiotics
(e.g., L. acidophilus and L. casei) to act as antibacterial agents against MRSA [105] (Table 1 and Figure 2).
More specifically, the growth of the pathogen was found to be inhibited and eliminated by 99% after
24 h at 37 ◦C incubation [105]. Moreover, in another study, three different probiotics (e.g., L. reuteri,
L. rhamnosus and L. salivarius) were tested against S. aureus infection on epidermal keratinocytes [97].
Overall, it was found that L. reuteri and L. rhamnosus (but not L. salivarius) reduced the ability of
the pathogen to induce keratinocyte cell death. This observation was directly associated with the
ability of L. reuteri to inhibit the adherence and invasion of the pathogen to keratinocytes while L.
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salivarius did not. Furthermore, the degree of protection was greater in L. reuteri than L. rhamnosus [97]
(Table 1). To conclude, given that S. aureus adheres with the epidermal keratinocyte cells via the
α5β1 integrin, it was suggested that both of the protective probiotics reduce keratinocyte cell death
by competitively excluding the pathogen from the integrin’s binding sites on these skin cells [97].
Finally, antibiotic properties of probiotics have been also documented in experimental settings where
wounds, infected with S. aureus, were treated with patches of L. fermentum. In these experiments, it was
shown an increased wound closure concomitant with production of nitric oxide (gNO) induced by
the probiotic [102] (Table 1 and Figure 2). In general, gNO is known to mediate the process of wound
healing through promoting the production of IL-1, TGF-β and cytokines all of which play a major role
in immune response and inflammation [103].
In addition, a number of other studies have focused on topical applications of kefir and other
fermented products because of their well-known anti-microbial and healing properties. Kefir is the
product of milk fermentation that contains grains characterized by specific starter cultures used in
the fermentation process [132]. These grains include (i) L. kefiri, (ii) species of the genera Leuconostoc,
Lactococcus and Acetobacter, (iii) lactose fermenting (e.g., K. marxianus) as well as (iv) non-lactose
fermenting (e.g., S. unisporus, S. cerevisiae and S. exiguous) yeasts [132]. However, there are many
more microorganisms found in Kefir grains including the species Lactobacilli, Streptococci, Lactococci,
Enterococci, Bacillus, etc. The composition of kefir grains varies depending on their origin and the
microorganisms they contain [133]. Another aspect that can change the effect and the composition of
kefir is the fermentation time and conditions [134–136]. Collectively, the antimicrobial activity of kefir
is the result of the composition of the product that is high in lactic acid, acetic acid, hydrogen peroxide
and bacteriocins all of which can have an effect on the growth of pathogens [137] (Table 1 and Figure 1).
Consequently, the complexity of the kefir grains (and kefir itself) has raised the scientific interest in the
context of exploring any potential effect on the growth of existing microorganisms in the human body.
To this end, when B. bifidum PRL2010 (a dominant microorganism in the human gut) was cultured
in the presence of kefir and/or kefiran (the polysaccharide produced by kefir), it was shown that the
glycans present in kefir had a beneficial role on the growth of the bacteria (perhaps due to the increased
transcriptional activation of genes related to the metabolisms of glycans) [138]. Furthermore, a few
studies have documented a protective effect of kefir on the wound healing process [79,115,137,139].
To this end, one of the biggest challenges in wound healing is the infection of burn wounds from the
antibiotic resistant pathogen P. aeruginosa. As a result, this pathogen is responsible for complications
on serious illnesses such as hospital acquired infections and sepsis syndromes [73–75]. Experiments on
burn wounds (after contamination with P. aeruginosa and then treatment with kefir) showed a reduction
of their size accompanied by reduced healing time when kefir was administered alone than in the
co-presence of silver sulfadiazine (a common topical antibiotic used for the treatment of P. aeruginosa
on burn wounds). Such findings highlight the potential pharmaceutical use of kefir on the treatment
of burn wounds [115]. Finally, in another study, burn wounds were contaminated with 8 different
pathogens (e.g., S. aureus, S. salivarius, S. pyogenes, P. aeruginosa, C. albicans, S. tympimurium, Listeria
monocytogenes and E. coli) and when kefir and/or kefiran were applied to the subject’s infected areas the
growth of these pathogens was considerably reduced [116].
3.2.2. Acne
Although not many studies have been conducted on the effect of pro- and prebiotics in acne,
a number of them suggest a potential preventive role of pro- and prebiotics on acne thereby mediating
its symptoms (Figure 1). More specifically, in a study utilizing a mixture of probiotics (L. acidophilus,
B. bifidum and L. delbrueckii), the side effects of minocycline administration (an antibiotic used
for the treatment of A. Vulgaris) were reduced while still being effective in exerting a synergistic
anti-inflammatory effect. These results suggest a potential use of the probiotic mixture as an alternative
treatment option against A. Vulgaris in addition to being capable of reducing adverse side effects
after chronic systemic antibiotic use [98]. Acne is enhanced in the presence of the bacterium P. acnes.
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On the other hand, S. epidermidis is naturally found on skin and has been shown to antagonize P. acnes
thus highlighting its therapeutic potential against acne [112] (Table 1 and Figure 2). In another study,
the therapeutic role of E. faecalis SL-5 on acne was also evaluated with results demonstrating that
bacteriocin (CBT SL-5; an antimicrobial compound produced by E. faecalis) was capable of reducing
inflammation suggesting the use of E. faecalis as an alternative approach to acne therapy thereby
avoiding the extensive use of antibiotics [113] (Table 1 and Figure 2).
Finally, despite the lack of literature on the effect of prebiotics to skin disease, konjac glucomannan
hydrolysates (GMH) have also been shown to inhibit A. Vulgaris and P. acnes by stimulating the growth
of probiotic microorganisms including lactobacilli. To this end, it is noteworthy that lactic acid bacteria
show selectivity towards a mannose, a glucose substrate (found in GMH), because of the nature and
accessibility of these sugars as carbon sources [118,119] (Table 2 and Figure 2).
3.3. Psoriasis
Psoriasis is a skin condition that causes a variety of symptoms including flaky skin (patches),
itchiness and redness of the area. It is a non-contagious disease and it can affect individuals of any
age [140]. There are different types of the disease including pustular psoriasis, psoriatic arthritis and
plaque. Even though the literature on the effects of probiotics to skin inflammation and dermatitis is
extensive, little is known on their effects on psoriasis. Nevertheless, a number of studies have been
conducted on the effect of pro- and prebiotics in psoriasis suggesting a potential preventive role of
their action by means of mediating the symptoms of the disease (Figure 1).
In general, studies on the role of the human epidermal microbiome in psoriasis and other skin
diseases revealed that S. epidermidis (although a permanent member of the normal human microbiota)
is second most prevalent staphylococcal species only to S. aureus [141]. To this end, a recent study was
shown that S. aureus was at significantly higher levels on diseased skin as opposed to S. epidermidis
and P. acnes both of which were shown to be in abundance on healthy skin thereby suggesting that
psoriasis is highly associated with the microbial load of the skin [142]. To this end, another study
has shown that the abundance of S. cerevisiae is decreased in psoriasis patients and that treatment
with dimethylfumarate (DMF) successfully restored its levels, a finding of utmost importance given
the well-known and beneficial immunomodulatory properties of this yeast species [143]. Moreover,
extensive research indicates a strong link between potential mediators of T cell activation and the
development of the disease. In particular, CD4+ T cells are linked with the development of psoriatic
arthritis whilst probiotics regulate T cells and reduce skin inflammation and dryness of the skin [144]
(Table 1 and Figure 2). In a recent case report, the probiotic microorganism L. sporogenes was successfully
used for the treatment of pustular psoriasis as evident by an overall improvement of the appearance
of lesions and patient’s general condition [99] (Table 1). A year later, Groeger et al., 2013 studied the
immuno-regulatory effects of B. infantis in patients with ulcerative colitis, chronic fatigue syndrome and
psoriasis. In the case of psoriasis, reduced plasma levels of C-reactive protein (CRP) and TNF-α were
observed thus highlighting the ability of B. infantis to reduce systemic pro-inflammatory biomarkers
and thus to act as a potential therapeutic approach in treating psoriatic disease [111] (Table 1 and
Figure 2).
Sodium butyrate is produced by the gut microflora [145] and it is known for its effect on cell
cycle [120], tumor growth factors (TGF-β) [121] and protease enzymes [122]. In various studies
utilizing human keratinocyte (HaCaT) cells it was shown that exposure to sodium butyrate induced
apoptosis by 50% through up-regulation of death receptor Fas with concomitant activation of caspases
8 and 3. In addition, increased expression levels of p52 and TGF-β were also shown suggesting
the involvement of cell proliferation and terminal differentiation as well [121]. Finally, a combined
treatment protocol with sodium butyrate and PD153035 (an epidermal growth factor receptor inhibitor)
was shown capable of enhancing keratinocyte differentiation [123]. Collectively, data suggest that
sodium butyrate can act as a potential additional approach to the management of hyperproliferative
skin diseases (including psoriasis) by modulating key cellular processes like apoptosis, proliferation
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and differentiation (Table 2 and Figure 2). To this end, a recent study examining the gut microbial
composition in psoriatic patients revealed that a reduction of butyrate microbiota producers may have
an impact on the established anti-inflammatory role of this short chain fatty acid [146] and thus explain,
at least partially, its preventive role in psoriasis (among other disorders) [110]. In fact, F. prausnitzii
(one of the most common microbial inhabitants of the large intestine) serves as an important source of
butyrate which, in turn, (i) provides energy for colonocytes, (ii) reduces oxidative stress and (iii) exerts
anti-inflammatory action (by triggering regulatory T cells) thereby conferring immune tolerance that
goes beyond the GI tract [38,100]. Finally, another study has shown that psoriatic patients possess
a substantially reduced number of F. prausnitzii when compared to healthy controls [101].
3.4. Photoaging
Skin aging is considered in the context of being either extrinsic or intrinsic. Extrinsic skin aging is
caused by a number of environmental factors like UVR exposure (photo aging), smoking and life style
habits (diet). In particular, photo aging is characterized by a specific phenotype that includes excessive
loss of skin moisture, formation of deep and thick wrinkles, age spots, discoloration, loss of collagen
and overall breakdown of the elastin network of the dermis, resulting in loss of skin elasticity [109].
To date, there are few studies investigating into the effects of probiotics/prebiotics to photo aging
(Figure 1). In one such study, when hairless mice were administrated probiotic-containing fermented
milk together with para-probiotic B. breve strain Yakult, and then subjected to UVB irradiation, it was
shown an improvement in elasticity and appearance of the skin [124] together with suppression of
elastase and IL-1β activity levels [125] (Table 1). These findings are in agreement with another study
where administration of L. plantarum HY7714 to hairless mice and human epidermal fibroblasts was
followed by UVB exposure and inhibition of MMPs-1,-2,-9 and -13 was recorded indicating rescued
procollagen expression accompanied by inhibition of Jun N-terminal kinase phosphorylation and c-Jun
expression levels. In addition, wrinkles formation and epidermal thickness were also reduced [147]
(Table 1 and Figure 2). Moreover, L. plantarum HY7714 was shown to increase the mRNA levels of
palmitoyl transferase (SPT) while reducing those of ceramide in human epidermal fibroblasts [148]
(Table 1 and Figure 2). Furthermore, Galacto-oligosaccharides (GOS; one of the main prebiotics found
in fermented food) were evaluated either alone or in the presence of probiotics (e.g., B. longum) in order
to assess their effects on skin disease and inflammation. It was shown that the combination of probiotics
and prebiotics prevented TEWL and reduced skin erythema whilst increasing the mRNA expression of
CD44, TIMP-1 and Col1 [149] (Table 2 and Figure 2). Finally, in other studies, oligo-saccharides were
also shown to prevent skin aging by modulating the expression of elastase-type proteases (through
elastin receptors) [150] and/or prevent damage to the skin immune system [151].
4. Conclusions
Scientific and commercial interest on probiotics and prebiotics as well as their effect on human
health and disease has increased in the last decade. The aim of this minireview article was to evaluate
the role of pro- and prebiotics on the normal function of healthy skin as well as their role in the
prevention and therapy of skin disease. Whilst a number of studies have determined the mechanisms
by which some of these individual microorganisms can affect specific processes involved in the
pathophysiology of skin disease, others have focused on more complex natural products (e.g., kefir)
known to contain a mixture of probiotics but nevertheless also capable of exerting a potent beneficial
effect. Overall, our manuscript favours the idea of the utilization of probiotics as a means of prevention
and/or treatment options in skin disease. Such an alternative approach can have a huge impact in the
context of therapy as it will aim to reduce the use of antibiotics and thus also reduce the side effects
associated with their chronic usage. However, in order to do so, the precise mechanism of their action
remains to be fully elucidated, whilst further studies need to explore their benefit in managing the
outcome(s) of skin disease(s) at the clinical setting.
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